Not Signed In - Xaliproden Reduces Occurrence Of Severe Peripheral Sensory Neuropathy Associated With Oxaliplatin-based Regimen, Study
Fri, 24 Feb 2006 05:00 AM EST
... Sanofi-aventis announced today that the final results of the Xenox trial showed that the experimental non-peptide compound xaliproden reduced the risk of occurrence of grade 3 peripheral sensory neuropathy (PSN) by 39% in patients treated with oxaliplatin injection-based therapy, without impacting the response rate of the oxaliplatin regimen... click link for more info. ...
Related Topics
- Peripheral Neuropathy
- Neuropathy
- Neuropathy - Hereditary
- Diabetic Neuropathy
- Hereditary neuropathy with liability to pressure palsies
- Faith-based Initiatives
- Peripheral Vascular Disease
- Community and Faith-Based Initiatives
- Faith-Based and Community Initiatives
- Vascular Disease
- Home & Hospice Care Survey
- Learning Disorders
- Charcot-Marie-Tooth Disease
- Auditory Neuropathy
- Peripheral Blood Stem Cells
- Immune System and Disorders
- Oxaliplatin Injection
- Peripheral Nerve Disorders
- Sensory Integration Disorder
- Multifocal Motor Neuropathy
email this page
print this page
bookmark this page
feedback on this page
